Inovio shares tumble as analysts say COVID-19 vaccine update left more questions than answers

Inovio Pharmaceuticals Inc. shares tumbled 22% Tuesday, a day after the company reported a wider-than-expected second-quarter loss and offered a limited update on its COVID-19 vaccine candidate which is currently in clinical trials.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.